5471-55-6

Basic information

• Product Name: 2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE
• Synonyms: cyclohexaneethylamine,hydrochloride;2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE;2-CYCLOHEXYL-ETHYLAMINE HCL;2-Cyclohexyl-ethylamin hydrochloride;2-CYCLOHEXYLETHYLAMINE HYDROCHLORIDE ---CRYSTALLINE---;Cyclohexaneethanamine, hydrochloride (1:1);Cyclohexaneethanamine Hydrochloride
• CAS NO: 5471-55-6
• Molecular Formula: C₈H₁₇N*ClH
• Molecular Weight: 163.69
• EINECS: 224-673-7
• Mol File: 5471-55-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 169.6 °C at 760 mmHg
• Flash Point: 51 °C
• Appearance: White/Crystalline Powder
• Density: 0.861 g/cm³
• Vapor Pressure: 1.53mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE(5471-55-6)
• EPA Substance Registry System: 2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE(5471-55-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 5471-55-6(Hazardous Substances Data)

Usage

General Description

2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE is a chemical compound made up of a cyclohexyl group and an ethylamine group, with a hydrochloride addition. It is commonly used as a precursor in the synthesis of pharmaceutical drugs and organic compounds. 2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE has a wide range of applications in the pharmaceutical and chemical industries, and its unique structure and properties make it a versatile building block for creating new compounds. It is also used as a catalyst in chemical reactions and as a reagent in organic synthesis. Furthermore, it has potential use in the treatment of neurological disorders due to its ability to interact with certain neurotransmitter receptors, making it an area of interest for further research and development.

InChI:InChI=1/C8H17N.ClH/c9-7-6-8-4-2-1-3-5-8;/h8H,1-7,9H2;1H

Upstream product

• 931-48-6 2-cyclohexylacetylene 
• 4442-79-9 cyclohexylethan-1-ol 
• 3399-73-3 2-(1-cyclohexenyl)ethylamine 
• 41763-92-2 2-(2-cyclohexylethyl)isoindoline-1,3-dione 
• 64-04-0 phenethylamine 

Downstream Products

• 864274-50-0 3-[(2-cyclohexylethyl)amino]-4-nitrobenzonitrile 
• 454646-66-3 3-(1H-imidazol-4-yl)propyl 2-cyclohexylethylcarbamate hydrogen maleate 
• 76649-96-2 c-hexylethyl isocyanate 
• 803736-98-3 C₁₈H₂₁ClN₂O₂ 
• 1392490-96-8 N-[1-({4-[(2-cyclohexylethyl)carbamoyl]benzene}sulfonyl)piperidin-4-yl]carbamic acid tert-butyl ester 
• 1132803-45-2 N-(2-cyclohexylethyl)-2-(2-(phenylsulfonyl)ethylthio)-nicotinamide 
• 902527-27-9 5-chloro-2-[4-chloro-3-[[(2-cyclohexylethyl)amino]carbonyl]phenyl]-3-pyridinecarboxylic acid methyl ester 
• 902527-35-9 3-chloro-6-[4-chloro-3-[[(2-cyclohexylethyl)amino]carbonyl]phenyl]-2-pyridinecarboxylic acid methyl ester 

Relevant articles and documents

ANTIVIRAL COMPOUNDS AND USE THEREOF

The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands

Previous studies have shown that several imidazole derivatives posses affinity to histamine H3 and H4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H3/H4 receptor subtypes, two series of 3-(1H-imidazol-4-yl)propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H4 receptor co-expressed with Gαi2 and Gβ1γ2 subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H3 receptor with Ki values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl)propyl pent-4-enylcarbamate with the highest affinity (Ki = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the Nτ-methylhistamine levels in mice with an ED 50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H4 receptor affinity (154-1326 nM).